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Abstract: Cardiogenic shock remains a challenging disease entity and is associated with significant morbidity and mortality. Temporary mechanical
circulatory support (MCS) can be implemented in an acute setting to stabilize acutely ill patients with cardiomyopathy in a variety of clinical situations.
Currently, several options exist for temporary MCS. We review the indications, contraindications, clinical applications, and evidences for a variety of temporary circulatory support options, including the intra-aortic balloon pump (IABP), extracorporeal membrane oxygenation (ECMO), CentriMag blood
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Introduction

With advancements in the management of coronary artery
disease, arrhythmias, and congenital heart disease, in addition to the development of predisposing comorbidities, more
and more patients are surviving heart failure (HF). There are
an estimated 825,000 new diagnoses of HF in a year, and
5.1 million adult Americans suffer from the disease.1 Though
there has been a significant reduction in mortality from HF
because of beta blockers, ACE-inhibitors, and automatic
implantable cardioverter defibrillators,2 many patients still
present with cardiogenic shock. This remains a challenge for
the practitioner and is associated with significant morbidity
and mortality.
Over the last several decades, temporary mechanical circulatory support (MCS) devices have been an effective means
of acute support in patients with cardiogenic shock or in the
setting of high-risk interventions such as revascularization or

ablation.3–6 There has been significant technologic development
in the field of circulatory support, with options including intraaortic balloon pump (IABP), extracorporeal membrane oxygenation (ECMO), CentriMag® pump, and several percutaneous
ventricular assist devices (pVADs), such as the TandemHeart®
and Impella® systems. When the method of temporary circulatory support is chosen and applied to the appropriate setting,
these devices can effectively aid in bridging patients to hemodynamic stabilization or more definitive management. This
review focuses on describing the hemodynamic goals, clinical
indications, and various device options for current generation
temporary MCS devices, in addition to highlighting ongoing
research and future directions in the field.

Goals of Temporary MCS

The primary hemodynamic goals of temporary MCS are to
decrease preload, decrease afterload, and augment cardiac
Clinical Medicine Insights: Cardiology 2014:8(S1)
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output. The end goal is to provide adequate organ perfusion
and oxygen delivery, which can bridge patients to recovery
or a more durable device, as well as support them through a
high-risk procedure (Table 1). Temporary MCS can be used
to mechanically unload the left ventricle and right ventricle
or provide biventricular support, with or without concomitant
ECMO to replace pulmonary gas exchange.
As MCS devices continue to develop, they must be practical in the real world of HF management. In addition to
providing optimization of hemodynamics, these devices must
have a desirable risk/benefit ratio with demonstrable safety
and efficacy. Additionally, they should be feasible and economical, with relative ease of insertion and availability.

Circulatory Support Options

Intra-aortic balloon pump. The IABP was first developed on the hemodynamic basis of diastolic augmentation
and counterpulsation. Kantrowitz and colleagues described
the first published experience with an intra-aortic circulatory
assist device in a case series of patients with cardiogenic shock
in 1968.3 A few years later, Scheidt and colleagues demonstrated improvement in hemodynamics, an increase in cardiac output by 500 mL/minute, and a decrease in lactate in
80 patients with cardiogenic shock.7
The IABP is placed via arterial access, most commonly
femoral, into the descending aorta (Ao). During diastole, the
balloon inflates, providing an augmented diastolic pressure and
coronary perfusion. During systole, the balloon deflates rapidly, creating a temporary vacuum that reduces aortic pressure
(ie, afterload) and enhances left ventricular (LV) unloading.
Overall effects of the IABP are a modest increase in cardiac
output and stroke volume; decrease in LV preload, LV enddiastolic pressure, LV wall stress, and afterload; and improved
coronary perfusion and systemic blood pressure (Table 2).
IABP placement initially developed as a surgical technique; however, it is now placed by interventional cardiologists
in the cardiac catheterization laboratory and can be emergently
Table 1. Indications for temporary mechanical circulatory support.
Cardiogenic shock due to:
• A
 cute myocardial infarction and related mechanical complications
• Acute decompensated heart failure
• Acute myocarditis
• Post-cardiotomy shock
• A
 cute rejection post-cardiac transplant with hemodynamic
compromise
High-risk interventions
• Percutaneous coronary intervention
• Ventricular tachycardia ablation
Bridge to LVAD or transplant
Right ventricular failure
Abbreviation: LVAD, left ventricular assist device.
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Table 2. Hemodynamic effects of mechanical circulatory support
devices.
IABP

ECMO

TandemHeart

Impella

Afterload

Reduced

Increased

Increased

Neutral

LV stroke
volume

Slight
increase

Reduced

Reduced

Reduced

Coronary
perfusion

Slight
increase

Unknown

Unknown

Unknown

LV preload

Slightly
reduced

Reduced

Reduced

Slightly
reduced

PCWP

Slightly
reduced

Reduced

Reduced

Slightly
reduced

 eripheral
P
tissue
perfusion

No significant
increase

Improved

Improved

Improved

Note: Adapted from Werdan K, Gielen S, Ebelt H and Hochman JS,
“Mechanical circulatory support in cardiogenic shock,” European Heart
Journal (2014) 35, 156–67, by permission from Oxford University Press and
European Society of Cardiology.

placed at the bedside in an unstable patient. It is considered a
safe and quick procedure in experienced hands. An alternative
to the femoral approach, which requires patients to be immobilized, is axillary placement, which allows patients to be out
of bed and is beneficial for prolonged use, such as in the bridge
to transplant (BTT) setting.8
Over the years, indications for IABP have broadened.
Cardiogenic shock secondary to acute myocardial infarction
(AMI) remains the most common indication. Additional
indications include postcardiotomy shock (PCS), refractory
HF, optimization, and bridge prior to cardiac surgery and
during high-risk cardiac procedures. IABP is contraindicated
in patients with aortic insufficiency and aortic dissection.
Relative contraindications also include sepsis and peripheral
vascular disease. Complications include bleeding, vascular
injury, thrombocytopenia, and infection (Table 3). Rates of
complication have been high in the past, but more recent large
studies suggest an overall angio-ischemic complication rate of
8–18%, with major limb ischemia in less than 1% of patients.9,10
The newer fiber optic IABP by Maquet (Fairfield, NJ, USA)
uses a smaller (7 Fr) catheter that may decrease vascular complications; however, use is not yet widespread.
Extracorporeal membrane oxygenation. ECMO
involves use of a centrifugal pump to drive blood from the
patient through an externalized membrane oxygenator system
for carbon dioxide and oxygen exchange before returning to
the patient’s arterial system. Cannulation sites include femoral artery and vein (venoarterial, VA) or internal jugular vein/
right atrium (RA) and common femoral vein (venovenous,
VV) (Fig. 1). In addition to assisting in gas exchange, VA
ECMO can augment cardiac output.
Advantages of ECMO include the ability to oxygenate
blood in hypoxemic states and unload both the right and left ventricles. Peripheral ECMO cannulas can be placed at the bedside

Temporary mechanical support
Table 3. Contraindications and complications associated with temporary circulatory support.
Device

Contraindications

Complications

All devices

Severe peripheral vascular disease
Irreversible neurologic disease
Sepsis*

Bleeding
Vascular injury
Infection
Neurologic injury

IABP

Moderate to severe aortic insufficiency
Aortic dissection
Abdominal aortic aneurysm
Contraindication to anticoagulation*

Thrombocytopenia
Thrombosis
Obstruction of arterial flow due to malposition
Aortic rupture or dissection
Air or plaque embolism

ECMO

Mechanically ventilated .7 days
Contraindication to anticoagulation

Thrombosis of circuit
Upper body hypoxia due to incomplete retrograde oxygenation
LV dilatation
Systemic gas embolism

CentriMag

Contraindication to anticoagulation

Thromboembolic events
Air embolism

TandemHeart

Ventricular septal defect
Moderate to severe aortic insufficiency
Contraindication to anticoagulation

Cannula migration
Tamponade due to perforation
Thromboembolism
Air embolism during cannula insertion
Inter-atrial shunt development

Impella

LV thrombus
Moderate to severe aortic stenosis
Moderate to severe aortic insufficiency
Mechanical aortic valve
Recent TIA or stroke
Aortic abnormalities
Contraindication to anticoagulation

Hemolysis
Pump migration
Aortic valve injury
Aortic insufficiency
Tamponade due to LV perforation
Ventricular arrhythmia

Note: *Relative contraindication.
Abbreviations: ECMO, Extracorporeal Membrane Oxygenation; IABP, Intra-aortic balloon pump; LV, left ventricular; TIA, transient ischemic attack.

in an emergency using a cut-down technique. The aim of ECMO
is to provide acute, temporary support or serve as a bridge to
more durable therapy. Complications include risk of limb ischemia, bleeding, and hemolysis. The American Heart Association
Guidelines for Cardiopulmonary Resuscitation state that ECMO
is reasonable to perform and its benefit outweighs risk in the setting of cardiac arrest or shock because of a potentially reversible
condition, such as myocarditis.11 Despite advancements in device
technologies described below, ECMO has been shown to have
comparable clinical outcomes when compared with percutaneously inserted ventricular assist devices (VADs).12

CentriMag. The CentriMag® (Thoratec Corporation) is
an extracorporeal, surgically implanted centrifugal pump that
can provide up to 10 L/minute of blood flow. It is a thirdgeneration continuous flow pump with a magnetically suspended rotor, which has minimal friction, thus reducing shear
force on red blood cells with less hemolysis. The CentriMag
system is currently Food and Drug Administration (FDA)
approved for LV support up to six hours. It is approved for
support when there is acute right ventricular (RV) failure for
up to 30 days (Humanitarian Use Device), and longer term
use is currently investigational only.13 The CentriMag system

VA-ECMO

VV-ECMO

Femoral artery

Internal jugular vein

Returning oxygenated
blood

De-oxygenated blood

Figure 1. A schematic representation of peripheral VA (VA ECMO) and VV-ECMO. From Cove ME, MacLaren G. Clinical review: MCS for cardiogenic shock
complicating acute myocardial infarction. Crit Care. 2010;14:235; originally published by BioMed Central with permission from MAQUET GmbH & Co. KG.
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can provide left and/or RV support with placement of outflow
(22 Fr) and inflow (32 Fr) cannulas in the left atrium (LA)/Ao
or RA/pulmonary artery (PA), respectively (Fig. 2). The pump
can also be used peripherally in an ECMO circuit.
In a multicenter study of 38 patients supported by the
CentriMag for various indications and a combination of left,
right, or biventricular support, the device provided effective short-term support with a 47% 30-day mortality rate
and low complication rate. The most common complications
were infection, bleeding, and thromboembolic neurologic
events (though three of four of these events were questionably related to device).14 Contraindications include bleeding
that precludes the use of heparin for anticoagulation during
device support.
Percutaneous ventricular assist devices. TandemHeart.
The TandemHeart System® (CardiacAssist, Inc.) is a LA to
femoral artery bypass system (Fig. 1). This pVAD consists of a
21F venous transseptal inflow cannula, a continuous flow centrifugal blood pump with an electromagnetically suspended and
driven impeller, and an arterial perfusion catheter. O xygenated
blood is withdrawn from the LA; which is accessed by standard
transseptal technique involving placement of the 21F cannula,
which contains 14 side holes and a large end hole; and pumped
to the systemic circulation via a 17F femoral artery catheter,
thereby bypassing the left heart. Patients should undergo an
aortogram with runoff to assess the degree of peripheral vascular disease prior to catheter insertion. RV support can be
achieved by placing the inflow cannula in the RA and outflow
cannula in the PA. The TandemHeart pump can also be surgically implanted similar to the CentriMag described above to
support either or both ventricles.
Thiele and colleagues first described the use of the
TandemHeart in 18 patients with AMI complicated by cardiogenic shock. The device was implanted for a mean of 4 ± 3 days,
and the use resulted in a significant improvement in cardiac
index (from 1.7 L/minute/m 2 to 2.4 L/minute/m 2), increase in
mean arterial pressure (from 63 to 80 mmHg), and decrease
in filling pressures. In all, 30-day mortality was reported to be
44%.15 The TandemHeart gained FDA approval in 2003.
Hemodynamically, the TandemHeart significantly reduces
preload and augments cardiac output, with the ability to pump

Figure 2. (A) A CentriMag blood pump and (B) a schematic diagram of
possible CentriMag cannulation sites: LA and Ao for LV support versus
RA and PA for RV support. Image courtesy of Thoratec Corporation.
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up to 4 L/minute. It has been shown to have superior effects
on hemodynamics than the IABP.16,17 Of note, the device is
preload dependent, with an ideal pulmonary capillary wedge
pressure maintained between 18 and 20 mmHg.18 Once the
pump is started, pulmonary capillary wedge pressure should
be monitored to ensure adequate filling and pump flow. Additionally, there is high risk of thromboembolism necessitating
the need for systemic anticoagulation with heparin.
Contraindications include ventricular septal defect (which
would then cause right to left shunting and hypoxemia), aortic
insufficiency, severe peripheral vascular disease, and inability to be on systemic anticoagulation. The TandemHeart has
several possible complications, and percutaneous placement
requires an experienced operator familiar with the technique of
transseptal puncture. Complications include distal limb ischemia, bleeding, infection, tamponade because of perforation at
the time of transseptal puncture, thromboembolism, and air
embolism at the time of insertion of large cannulae.19,20
Impella system. The Impella® 2.5 system (Abiomed) is a
9-Fr catheter-mounted, 2.5 L/minute, impeller-driven, axialflow pump that is placed in a retrograde fashion across the
aortic valve via a cardiac catheterization procedure (Fig. 3).
The pigtail-tipped catheter sits in the left ventricle and pumps
blood out to the ascending Ao. It received FDA approval in
2008. The 5.0 L/minute Impella® 5.0 or Impella® LD (both
FDA approved in 2009) is larger and requires surgical cut
down of the femoral or axillary artery or an open heart procedure, respectively. These devices can be inserted for short-term
support, typically up to five days.19
The Impella requires systemic anticoagulation. Complications include bleeding, vascular injury, infection, and hemolysis. Another concern is pump migration if the catheter becomes
dislodged in any way. Contraindications include LV thrombus,
moderate aortic stenosis or aortic insufficiency, recent stroke or
TIA, and structural abnormalities of the Ao.19
Total artificial heart (TAH). The TAH is a complete
cardiac replacement strategy, first successfully implanted
in 1982. 21 The only current FDA-approved device in the
United States as a BTT is the SynCardia temporary TAH
(SynCardia Systems, Inc). It may be used for destination
therapy under the Humanitarian Use Device designation
in the United States. It consists of a 70-cc pneumatically
driven pump with tilting disk valves and short outflow grafts
replacing both ventricles, the proximal Ao and PA, and the
four valves. A left ventricle is connected to the LA via a left
atrial inflow connector and to the Ao via an outflow cannula.
A right ventricle is connected to the RA via a right atrial
inflow connector and to the PA via an outflow cannula. The
ventricular drivelines tunnel through the chest wall and connect to the external console. Size requirements include a body
surface area $1.7 m 2 and chest AP diameter $10 cm. 22,23
Additionally, there is a smaller, 50 cc, TAH in development
for patients with a body surface area of 1.2–1.79 m 2 , which
may help overcome the primary size contraindication for

Temporary mechanical support

Figure 3. An illustration of options for MCS: (A) IABP, (B) TandemHeart, and (C) Impella. From Desai NR, Bhatt DL. Evaluating percutaneous support for
cardiogenic shock: data shock and sticker shock. Eur Heart J. 2009;30:2073–2075, by permission from Oxford University Press and European Society of
Cardiology.

placement. In a single-center experience of 101 patients using
SynCardia TAH as a BTT, mean support time was 87 days
with 68.3% survival rate. Major adverse events were stroke
(7.9%) and reoperation because of hemorrhage (24.7%). 23 The
Freedom® portable driver, a wearable system that runs the
SynCardia TAH and allows discharge to home, was recently
FDA approved on June 26, 2014.

Clinical Indications for Temporary MCS

Cardiogenic shock because of AMI. Ischemic heart
disease continues to be the most common cause of HF, and
cardiogenic shock is still a frequent complication of AMI. In
fact, most early studies of cardiogenic shock were performed
in patients with AMI, and the majority of data regarding the
use of MCS are still in this setting.
With its favorable hemodynamic effects of decreased
afterload and increased coronary perfusion, it is not surprising that the American College of Cardiology and American
Heart Association (ACC/AHA) initially deemed that there
was enough evidence that IABP placement should be performed when managing cardiogenic shock in the setting of
ST-elevation myocardial infarction (STEMI). However,
much of these data were based on registries, with poor level of
evidence, and the newest guidelines have actually changed the
recommendation for IABP as well as other LV assist devices
to reasonable to perform rather than should be performed.24 In
fact, recent data suggest that IABP may have less of a role in
acute management of STEMI with cardiogenic shock than
was previously thought.25
Sjauw and colleagues published a recent two-part metaanalysis of IABP utilization in STEMI.25 The first included
seven randomized trials encompassing a total of 1009 STEMI
patients. In this population, IABP did not show any benefit

for 30-day survival. The second looked specifically at studies
of STEMI patients with cardiogenic shock and IABP. They
divided the studies based on treatment: thrombolysis versus
primary percutaneous coronary intervention (PCI). Though
patients receiving thrombolytics and IABP placement had an
18% decrease in 30-day mortality (P , 0.0001) compared to
those without the IABP, patients initially revascularized with
PCI rather than thrombolytics had a 6% increase in 30-day
mortality (P , 0.0008).25 It should be noted, however, that
the nine studies in this meta-analysis were all cohort studies, as there had not been any randomized controlled trials
of IABP use in AMI complicated by shock. In a Cochrane
Database of Systematic Reviews’ meta-analysis of six eligible
and two ongoing studies comparing IABP to either standard
treatment or to percutaneous left assist devices in 190 patients
with AMI and cardiogenic shock, the all-cause 30-day mortality hazard ratio was 1.04 (95% CI, 0.62–1.73).26
In an attempt to address the lack of data on utility of
IABP in shock with AMI, the IABP-SHOCK II investigation
randomized 600 patients expected to undergo early revascularization (PCI or coronary artery bypass grafting) in a prospective, open-label, multicenter trial to IABP or no IABP.27
The primary endpoint of 30-day mortality was met in 39.7%
of patients in the IABP group and 41.3% of patients without IABP (P = 0.69). No significant differences in secondary
endpoints or rates of major bleeding, peripheral ischemic
complications, sepsis, or stroke were found. There was a nonsignificant trend toward higher rate of VAD placement in the
group without IABP. Also, 10% of patients randomized to the
control group underwent IABP placement; most of them were
protocol violation. Follow-up data at 12 months did not show
any benefit in the IABP-treated group.28 These data, together
with the meta-analysis by Sjauw et al, suggest that in patients
Clinical Medicine Insights: Cardiology 2014:8(S1)
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who are successfully revascularized with primary PCI (95.8%
of patients in IABP-SHOCK II), IABP may not provide
additional benefit.
In a head-to-head randomized comparison between the
TandemHeart and IABP in patients undergoing primary
PCI, hemodynamics were significantly improved in the pVAD
group; however, there were more complications with similar
30-day mortality rates (though the study was not powered for
mortality). Of note, in this study, a high percentage of patients
received thrombolytics and there was no screening aortogram/
aortoiliac runoff prior to placement of either device.16 Another
study in patients with mostly myocardial infarction (MI)related cardiogenic shock confirmed the hemodynamic benefit
of the TandemHeart, though a lack of survival benefit, when
compared with IABP.17
Given the high mortality in patients with STEMI complicated by shock, continued attention has been focused at
unloading the left ventricle and improving hemodynamics
and survival in this patient population. With mixed data from
IABP trials and the risks associated with the placement of the
TandemHeart, focus was shifted to the Impella 2.5. The use of
the Impella 2.5 has also improved outcomes in patients with
shock in the setting of acute ischemia, especially when initiated early, ie, prior to revascularization.29 The EUROSHOCK
Registry was a retrospective study of 120 patients with cardiogenic shock because of AMI undergoing implantation of
Impella 2.5. There was a decrease in lactate levels at 48 hours
suggesting improved organ perfusion, but 30-day mortality remained high at 64.2%.4 Patients who received Impella
2.5 support prior to primary PCI in the setting of AMI and
cardiogenic shock, rather than after PCI, fared better.30 The
Impella 2.5 has also shown beneficial LV remodeling and
unloading in anterior STEMI patients without cardiogenic
shock.31
When compared with the IABP, the Impella 2.5 more
substantially improves hemodynamics though no randomized
trials have been powered for a primary endpoint of mortality.32 The most recent RE-COVER II trial, which also aimed
to compare the Impella 2.5 with the IABP, was terminated
because of incomplete enrollment.33
Cardiogenic shock complicating AMI remains the leading cause for need of LV support. Though pVADs have shown
an improvement in hemodynamics, further larger, randomized
studies are necessary to demonstrate a clear mortality benefit.
High-risk PCI in the setting of cardiomyopathy. pVAD
has an additional role in ischemic heart disease as an adjunct to
high-risk PCI in the setting of severe LV dysfunction and/or
cardiogenic shock. ECMO-assisted primary PCI in the setting of cardiogenic shock complicating AMI has been shown
to improve survival.34,35 The IABP has been used for years
to provide mechanical support in high-risk interventional
settings; however, as outlined above, it provides only modest
improvement in hemodynamics and cannot provide actual
circulatory support.
80
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Both the TandemHeart and Impella 2.5 can be used
at the time of high-risk PCI, with periprocedural insertion
and removal in the cardiac catheterization lab. Aragon and
colleagues published their early results using the TandemHeart in a small (n = 8) group of patients undergoing highrisk PCI. 36 All patients had low LV systolic function and
multi-vessel disease, with three patients having left main
disease. They described procedural success and ability to
obtain short-term hemodynamic stability in all patients. Two
small studies, including the PROTECT I study, have demonstrated feasibility and efficacy of the Impella 2.5 during
high-risk PCI in similar patient cohorts. 37,38 A retrospective
analysis of the Europella Registry (144 patients) also demonstrated safety and feasibility, with a 5.5% 30-day mortality rate. 39 Both the TandemHeart and the Impella 2.5 have
similar procedural, in-hospital and long-term outcomes in
their prospective high-risk PCI cohorts, although there are
no randomized studies comparing these two devices in this
clinical situation.40
The subsequent and larger prospective, randomized controlled trial, PROTECT II, compared periprocedural support
using the Impella 2.5 versus IABP in 452 patients with systolic
HF (mean ejection fraction [EF] 24%) undergoing high-risk
PCI. After 69% of expected enrollment, the trial was stopped
early because of futility. Though support with the Impella 2.5
provided a superior hemodynamic profile, there was no significant difference in the primary endpoint of 30-day major
adverse cardiovascular events (MACE). However, at 90 days,
the non-significant difference between the two groups’ 30-day
MACE rate did trend toward a wider difference (40.6% versus
49.3%, P = 0.066) in the intention-to-treat analysis and a significant difference in the per protocol analysis (40.0% versus
51.0%, P = 0.023, yielding a relative risk reduction of 22%).5
Ventricular tachycardia. Ventricular tachycardia (VT)
frequently accompanies end-stage cardiomyopathy and can
lead to significant hemodynamic instability. Medical management and defibrillator therapy alone may not be enough
to control VT; therefore, catheter ablation strategies are now
more frequently pursued, especially when involving infarctrelated scar. However, induction of VT during activation
mapping can lead to further instability, and in this setting,
substrate- and pace-mapping techniques can alternatively
be used but may not be effective in eliminating VT. Though
IABP support is indicated for decompensation in the setting
of refractory arrhythmia, its optimal use can be challenging
during VT. Percutaneous support devices can assist during
arrhythmia induction by lending hemodynamic stability.
Friedman and colleagues first described the successful
use of the TandemHeart in a single patient undergoing endocardial and epicardial VT ablation.6 This has been shown to
allow identification and ablation of a greater number of VT
foci.41 In this retrospective study, there was no difference in
long-term outcomes between the TandemHeart-supported
group and the substrate-mapped strategy group; however,

Temporary mechanical support

the pVAD group may have been a sicker cohort to begin with
since patients were not randomized.
The Impella 2.5 has also been successfully used during unstable VT ablation as described in case reports and a
few small studies.42–44 Miller and colleagues retrospectively
showed that the use of the Impella 2.5 allowed longer time
in induced VT (66.7 versus 27.5 minutes; P = 0.03) as well as
fewer early terminations of VT for hemodynamic instability
(1.0 versus 4.0; P = 0.001). Hemodynamically, they demonstrated that there was no difference in cerebral deoxygenation
as monitored by cerebral oximetry, hypotension, or markers
of perfusion.43 In a subsequent non-randomized, prospective study of scar-mediated VT in patients with severe LV
dysfunction, the same group conducted the percutaneous
hemodynamic support with Impella 2.5 during scar-related
ventricular tachycardia ablation (PERMIT1) study. They
demonstrated that during fast simulated VT, more favorable
hemodynamics were achieved with pVAD support. Interestingly, they employed cerebral oximetry with a threshold of
55% to guide duration of VT mapping. Cerebral desaturation
(#55%) occurred in 53% of patients tested without Impella
2.5 support but in only 5% of patients with full support.44
These studies suggest that the use of pVAD support during
unstable VT ablation will allow a more complete, safe, and
successful procedure.
Bridging refractory HF. Temporary MCS may be necessary to decide on more definitive therapy (bridge to decision,
BTD) or to optimize patients prior to LVAD or transplant
(bridge to bridge or BTT). Though patients requiring mechanical support do worse early on, if they survive to transplant, they
do as well as their counterparts who did not require mechanical support.45 Until recently, the only percutaneous option in
this setting was IABP or ECMO; however, prolonged use is
associated with complications (see Intra-Aortic Balloon Pump
and Extracorporeal Membrane Oxygenation sections).46,47
Although more durable mechanical support may more effectively bridge a patient to definitive therapy, surgical placement
may be too risky in a patient with acute cardiogenic shock, and
percutaneously placed VADs may be more practical in this
situation.48,49
pVADs have been utilized in a variety of clinical situations involving patients who may eventually require more permanent support or heart transplantation. The TandemHeart
was first used as a BTT in 2005 for six days until successful
heart transplantation.50 Gregoric and colleagues described
the use of the TandemHeart as a bridge to a long-term axialflow LVAD in nine patients with acute refractory cardiogenic shock.51 Brinkman et al studied the TandemHeart in
11 patients as BTT or potential recovery and an additional
11 patients with questionable neurologic status or multiorgan
failure as BTD. In all, 4 of the latter 11 patients survived:
1 recovered, 1 received an LVAD, 1 received an LVAD and
then transplant, and 1 underwent transplantation. The other
seven died after a mean of three days of support. The authors

stated that pVAD insertion allowed time for more complete
evaluation before proceeding with long-term therapy, which
is key to the success of the more durable therapies. Of the
BTT population, 1 died because of infectious complications,
10 had successful TandemHeart explants with 3 subsequently
receiving a durable LVAD (2 eventually were transplanted),
5 received a heart transplant, and 2 were recovered.52 Bruckner
and colleagues examined the hemodynamic effects of the
TandemHeart in five patients with refractory cardiogenic
shock.53 They demonstrated an improvement in cardiac index,
mean arterial pressure, mixed venous oxygen saturation, and
urine output from baseline (Table 4). The device decreased
central venous pressure; however, it did not have a significant
effect on pulmonary capillary wedge pressure or renal function. After an average duration of 7.6 ± 3.2 days support, all
patients were successfully bridged to transplant. The Impella
has also been used as a BTT. Garatti and colleagues described
use of the Impella LD or LP in six patients as BTT, two of
whom required VAD support and died.54 The authors concluded that the Impella device may be utilized to provide
support until long-term device placement (as a double bridge)
rather than directly to transplant. In summary, patients with a
dramatic hemodynamic improvement with pVAD placement
may benefit from urgent transplant listing, whereas those who
do not demonstrate such clinical improvement may benefit
from first being bridged with more durable support.
One of the most common nonischemic causes of acute
HF that may require mechanical support as a bridge to recovery (BTR) is acute myocarditis. Though patients with acute,
fulminant myocarditis have been shown to have better longterm outcomes than those with non-fulminant myocarditis,
they often initially require temporary support if inotropes
and IABP have failed.55,56 Several case reports and series
have demonstrated the utility of pVAD insertion for this
purpose.57–59 Chandra and colleagues described the first three
patients with acute myocarditis who successfully recovered on

Table 4. Hemodynamic values before and after TandemHeart
placement.
Before

After

Cardiac index, L/(min*min2)

1.9 ± 0.3

3.5 ± 0.8

Pressors used (n)

2.4 ± 1.1

1.0 ± 0.7

Mean arterial pressure (mmHg)

69 ± 12.5

91 ± 4.3

Pulmonary capillary wedge
pressure (mmHg)

30.4 ± 8.6

21.8 ± 4.3

Mixed venous oxygen saturation (%)

45.4 ± 14.3

71.4 ± 7.5

Central venous pressure (mmHg)

21.2 ± 7.4

12.8 ± 5.9

Urine output (mL/24 hr)

1,861 ± 988

4,314 ± 1.34

Blood urea nitrogen (mg/dL)

46.2 ± 44.2

44.6 ± 33.1

Creatinine (mg/dL)

1.8 ± 0.7

1.6 ± 0.5

Notes: Values are expressed as mean ± SD. Adapted with permission from
Bruckner et al.53 Copyright 2008 by the Texas Heart Institute.
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the TandemHeart, with a mean duration of support of five
days.58 Khalife and Kar similarly described two patients with
acute fulminant myocarditis who were successfully toward
BTR using the TandemHeart.59 When deciding on the mode
of support (temporary versus more permanent) in patients
with acute myocarditis, it is important to identify those who
may require more durable support. Though a pVAD can be
used as a bridge to a bridge (ie, to a durable LVAD), some
patients, such as those with giant cell myocarditis, may benefit
from more durable, or even biventricular, support from the
outset as recovery times are longer and may entail waiting for
heart transplantation.56
Additionally, pVADs can be used in patients presenting
with allograft rejection. IABP and ECMO are often used
in this situation to stabilize patients while they are being
treated for rejection; however, they may require longer-term
support for recovery. Rajagopal and colleagues describe
a patient who had biventricular pVAD support using the
Impella 2.5 for the LV and the TandemHeart for refractory
RV failure.60 Both devices were successfully weaned and
removed after adequate treatment of the patient’s cardiac
allograft rejection.
Optimal timing of device implantation in these patients
is imperative. The Interagency Registry for Mechanically
Assisted Circulatory Support (INTERMACS) has defined
seven clinical profiles of patients being considered for VAD
therapy (Table 5).61 INTERMACS profile 1 (crash and burn)
and profile 2 (sliding on inotropes) patients should be considered for VAD, either temporarily or permanently, very
quickly, although clinical outcomes for INTERMACS profile 1 patients receiving a surgically implanted, durable VAD
are worse than for those in higher INTERMACS profiles.62
Additionally, pre-implantation risk factors for mortality after
durable LVAD implantation have been identified in several
studies.63,64 Most formalized risk models, however, are for
transplant candidacy and originate from ambulatory data.
These data are less applicable to the inpatient population
requiring pVADs; and therefore, patient identification should
be based on INTERMACS profile and clinical judgment.
Additionally, a feasible exit strategy should be identified prior
to implantation.

Table 5. INTERMACS profile descriptions.61
Profile 1: Critical cardiogenic shock. (“Crash and burn”).
Profile 2: Progressive decline. (“Sliding on inotropes”).
Profile 3: Stable but inotrope dependent. (“Dependent stability”).
Profile 4: Resting symptoms.
Profile 5: Exertion intolerant.
Profile 6: Exertion limited.
Profile 7: Advanced NYHA III.
Abbreviations: INTERMACS, Interagency Registry for Mechanically Assisted
Circulatory Support; NYHA, New York Heart Association.
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Postcardiotomy shock. PCS is one of the leading causes
of death after cardiac surgery, usually because of multiorgan
failure. Approximately 0.2–6% of patients undergoing cardiac
surgery develop PCS with survival to discharge ranging from
19.5% to 52.4%.65 IABP and inotropic therapy alone may
not suffice in patients who develop PCS when weaning off
cardiopulmonary bypass (CPB). The use of ECMO, especially
in patients with hypoxia or biventricular failure, is a common practice in this setting. Rastan and colleagues described
517 patients receiving ECMO support for PCS. The average
duration of support was 3.28 days, and 74.1% of patients also
had an IABP. In this cohort, 63.3% weaned successfully off
ECMO; however, only 24.8% of all patients made it to hospital discharge. Cumulative survival was 17.6% at six months,
16.5% at one year, and 13.7% at five years. Unfortunately, these
patients still have a high in-hospital mortality rate despite
complete MCS.66
Pitsis et al first described the use of the TandemHeart
in two patients with postcardiotomy cardiac failure.67 They
then described a larger cohort of 11 patients who underwent
TandemHeart support postcardiotomy, with the most common indication being failure to wean from CPB. The mean
duration of support was 88 hours, and 72.2% of patients were
successfully weaned off the pVAD. Survival to discharge was
54.54%. The major complication was pericardial bleeding.68
The Impella also has been used in the postcardiotomy
setting. Siegenthaler et al studied 24 patients with PCS
undergoing Impella implantation (with or without IABP)
and 198 patients who underwent IABP alone. The use of the
Impella improved survival over IABP alone in patients with a
residual cardiac output of 1 L/minute.69 The CentriMag has
also been demonstrated to be of more benefit when placed in
patients in the operating room who have failed to wean from
bypass rather than after decompensation in the intensive
care unit postoperatively.70 The CentriMag system has also
been implanted with an ECMO configuration in 14 patients
with PCS. Seven patients were successfully weaned, and six
patients were discharged home. All of these patients remained
on IABP support for at least five days after removal of the
CentriMag system.71
The Impella 5.0 was studied in the single-arm prospective feasibility study, RECOVER-1. A total of 16 patients
underwent implantation for PCS. The primary safety
endpoint of death or stroke at 30 days or discharge was noted
in two patients (94% survived to 30 days, and of those, 93%
were weaned off MCS). In all, 13 patients recovered their
native cardiac function and were successfully weaned. The
last patient required VAD implantation as a BTT. There
were significant improvements in hemodynamic parameters,
including mean arterial pressure and cardiac index.72 In a
larger retrospective review of 47 patients undergoing Impella
implantation for acute cardiogenic shock, of those who had
PCS (68% of patients), the one-year survival was 71.8%.73 The
Impella 5.0, which crosses the aortic valve, has been success-
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fully placed in a patient with PCS after bioprosthetic aortic
valve replacement.74
Despite major technological advances, PCS remains a
serious cause of mortality in patients undergoing cardiac surgery, with only about 25% of patients making it to hospital
discharge.75 Timely initiation of mechanical support, prior to
complete loss of cardiac function, is imperative. Appropriate
triage of these patients to centers skilled in the treatment of
PCS and with the ability of offering advanced HF therapies is
also of utmost importance in order to improve outcomes.
RV support. Acute RV failure can occur in several settings, including cardiogenic shock and postoperatively after
heart transplant or surgical LVAD placement. Up to 50% of
acute inferior wall MIs involve the RV. About 2–3% of heart
transplant patients, and anywhere from 5 to 44% of patients
undergoing LVAD, will develop RV failure perioperatively,
depending on the definition of RV failure (Table 6).76,77 In
fact, there are several risk models designed to predict postoperative RV failure.78–80
Preoperatively, RV function can be modified with pulmonary vasodilators, inotropes, and optimization of RV
preload; however, in refractory situations, mechanical support
may be necessary. The RV differs from the LV in that it usually recovers more rapidly. Therefore, temporary assist devices
are preferred. If pulmonary dysfunction and oxygenation are
issues, ECMO is the best option. Other strategies include the
use of percutaneous right ventricular assist devices (pRVADs)
such as the TandemHeart or CentriMag systems as previously
described.81
The use of the TandemHeart for RV support was first
described by Giesler and colleagues in a 57-year-old female with
RV infarction.82 In a retrospective study of nine patients with
primary RV failure, Kapur et al described significantly improved
outcomes after insertion of a pRVAD. Patients underwent
TandemHeart placement via right internal jugular-to-femoral or
bifemoral cannulation to bypass blood from the RA to the main
PA. The mean arterial pressure increased from 57 to 75 mmHg,
right atrial pressure decreased from 22 to 15 mmHg, cardiac
index increased from 1.5 to 2.3 L/minute/m2, mixed venous
oxygen saturation increased from 40% to 58%, and RV stroke
work increased from 3.4 to 9.7 g⋅m/beat. Four patients died
during hospitalization, and those who survived had a shorter
Table 6. Definition of Right Ventricular Failure after LVAD
Implantation.76,77
1. Evidence of RV dysfunction with CI ,2.2 l/min/m2 and CVP of
18–22 mmHg
2. Need for postoperative intravenous inotropic support
for .14 days, inhaled NO for .48 hours, right-sided circulatory
support such as RVAD, or hospital discharge on an inotrope
3. Absence of other causes explaining circulatory failure
Abbreviations: CI, cardiac index; CVP, central venous pressure; LVAD, left
ventricular assist device; NO, nitric oxide; RV, right ventricular; RVAD, right
ventricular assist device.

time to pRVAD implantation (0.9 days).83 In the more recent,
larger, multicenter THRIVE Registry, Kapur and colleagues
found similar outcomes in 40 patients undergoing TandemHeart RV support.84
An RVAD may be temporarily placed in patients with RV
failure after LVAD implantation. Takagaki et al have described
successful conversion of a TandemHeart pLVAD to pRVAD
after implantation of the HeartMate XVE LVAD.85 Similarly,
Anderson and O’Brien described the use of the Impella LP
device during HeartMate II implantation.86 The Impella RP
(specifically designed for the right ventricle) can also be utilized
for RV support and can deliver up to 4.8 L/minute. The inflow
is in the inferior vena cava and the outflow in the PA, and the
axial-flow pump is placed across the tricuspid and pulmonic
valves in an antegrade fashion. This device is currently under
investigation. It should be noted that there are no commercially
available percutaneous devices, specifically for RV support, in
the US.

Conclusion

Major technological advancements have enabled temporary
MCS to take on a larger role in the treatment of HF over
the last decade. Indications have broadened widely from its
early uses. There are several considerations to keep in mind
when deciding whether a patient is appropriate for temporary MCS. One must identify which device would suit him or
her best, weighing the pros and cons of each method of support. Most patients requiring temporary support are acutely
and critically ill, but an effort must be made to make decisions early when possible, ideally prior to a crash and burn
(ie, INTERMACS 1 profile) situation. There must also be an
exit strategy prior to insertion of temporary MCS, as its role
is primarily for the short term as a BTR, permanent support,
or transplantation.
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